Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 103

1 1. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long‐term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18(3):348–371.

2 2. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010; 28(6):1011–1016.

3 3. Hammond C, Abrams JR, Syrjala KL. Fertility and risk factors for elevated infertility concern in 10‐year hematopoietic cell transplant survivors and case‐matched controls. J Clin Oncol. 2007; 25(23):3511–3517.

4 4. Littley MD, Shalet SM, Morgenstern GR, Deakin DP. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Q J Med. 1991; 78(287):265–274.

5 5. Cust MP, Whitehead MI, Powles R, et al. Consequences and treatment of ovarian failure after total body irradiation for leukaemia. BMJ. 1989; 299(6714):1494–1497.

6 6. Corson SL, Sullivan K, Batzer F, et al. Gynecologic manifestations of chronic graft‐versus‐host disease. Obstet Gynecol. 1982; 60(4):488–492.

7 7. Practice Committee of the American Society for Reproductive Medicine. Smoking and infertility. Fertil Steril. 2004; 81(4):1181–1186.

8 8. Buchbinder D, Brazauskas R, Bo‐Subait K, et al. Predictors of Loss to Follow‐Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplant. 2020; 26(3):553–561.

9 9. Blazar RB, Murphy WJ, Abedi M. Advances in graft‐versus‐host disease biology and therapy. Nat Rev Immunol. 2012; 12:443–458.

10 10. Epstein O, Thomas HC, Sherlock S. Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft‐versus‐host disease. Lancet. 1980; 1(8179):1166–1168.

11 11. Wenzel J, Lucas S, Zahn S, et al. CXCR3<–>ligand‐mediated skin inflammation in cutaneous lichenoid graft‐versus‐host disease. J Am Acad Dermatol. 2008; 58(3):437–442.

12 12. Kawasaki H, Takayama J, Ohira M. Herpes zoster infection after bone marrow transplantation in children. J Pediatr. 1996; 128:353–356.

13 13. Atkinson K, Meyers JD, Storb R, et al. Varicella‐zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation. 1980; 29:47–50.

14 14. Wainwright MS, Martin PL, Morse RP, et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol. 2001; 50(5):612–619.

15 15. Shiroshita K, Mori T, Kato J, et al. Clinical characteristics of human herpesvirus‐6 myelitis after allogeneic hematopoietic stem cell transplantation and its favorable outcome by early intervention. Bone Marrow Transplant. 2019; 55:939–945.

16 16. Youssef S, Rodriguez G, Rolston KV, et al. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine‐breakthrough infections, 1989–2005. Medicine (Baltimore). 2007; 86:69–77.

17 17. Hoyle C, Goldman JM. Life‐threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. Bone Marrow Transplant. 1994; 14:247–252.

18 18. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood. 1990; 75:1583–1586.

19 19. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft‐versus‐host‐disease is associated with long‐term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000; 95:3683–3686.

20 20. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012; 54(8):1053–1063.

21 21. Joseph RW, Couriel DR, Komanduri KV. Chronic graft‐versus‐host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. J Support Oncol. 2008; 6:361–372.

22 22. Creamer D, Martyn‐Simmons CL, Osborne G, et al. Eczematoid graft‐vs‐host disease: a novel form of chronic cutaneous graft‐vs‐host disease and its response to psoralen UV‐A therapy. Arch Dermatol. 2007; 143:1157–1162.

23 23. Sullivan KM, Shulman HM, Storb R, et al. Chronic graftversus‐host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981; 57(2):267–276.

24 24. Jacobsohn DA, Kurland BF, Pidala J, et al. Correlation between NIH composite skin score, patient‐reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood. 2012; 120:2545–2552.

25 25. Patel AR, Turner ML, Baird K, et al. Voriconazole induced phototoxicity masquerading as chronic graft‐versus‐host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2009; 15(3):370–376.

26 26. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long‐term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006; 12:138–151.

27 27. Schubert MM, Sullivan KM. Recognition, incidence, and management of oral graft‐versus‐host disease. NCI Monogr. 1990;( 9):135–143.

28 28. National Cancer Institute. Oral and Dental Management Before Cancer Therapy. 2013. Available from: http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessional/page3 (accessed 24 August 2020).

29 29. Picciotto A, Campo N, Brizzolara R, et al. Chronic hepatitis induced by Jin Bu Huan. J Hepatol. 1998; 28:165–167.

30 30. Harvey J, Colin‐Jones DG. Mistletoe hepatitis. Br Med J ( Clin Res Ed). 1981; 282:186–187.

31 31. Centers for Disease Control and Prevention (CDC). Hepatic toxicity possibly associated with kava‐containing products – United States, Germany, and Switzerland, 1999–2002. MMWR Morb Mortal Wkly Rep. 2002; 51:1065–1067.

32 32. Majhail NS, DeFor T, Lazarus HM, Burns LJ. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant. 2008; 14:790–794.

33 33. Akpek G, Chinratanalab W, Lee LA, et al. Gastrointestinal involvement in chronic graft‐versus‐host disease: a clinico pathologic study. Biol Blood Marrow Transplant. 2003; 9(1):46–51.

34 34. Spiryda LB, Laufer MR, Soiffer RJ, Antin JA. Graft‐versus‐host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant. 2003; 9(12):760–765.

35 35. Grigg AP, Underhill C, Russell J, Sale G. Peyronie’s disease as a complication of chronic graft versus host disease. Hematology. 2002; 7(3):165–168.

36 36. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015; 21(3):389–401.

37 37. Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed chronic kidney disease in long‐term survivors of hematopoietic cell transplantation. Cancer. 2008; 113(7):1580–1587.

38 38. Gurney JG, Ness KK, Rosenthal J, et al. Visual, auditory, sensory, and motor impairments in long‐term survivors of hematopoietic stem cell transplantation performed in child‐hood: results from the Bone Marrow Transplant Survivor Study. Cancer. 2006; 106:1402–1408.

39 39. Majhail NS, Ness KK, Burns LJ, et al. Late effects in survivors of Hodgkin and non‐Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Biol Blood Marrow Transplant. 2007; 13:1153–1159.

40 40. Brennan BM, Shalet SM. Endocrine late effects after bone marrow transplant. Br J Haematol. 2002; 118:58–66.

41 41. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplantation Survivor Study. Blood. 2007; 109:1765–1772.

42 42. Majhail NS, Challa TR, Mulrooney DA, et al. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009; 15:1100–1107.

43 43. Ranke MB, Schwarze CP, Dopfer R, et al. Late effects after stem cell transplantation (SCT) in children – growth and hormones. Bone Marrow Transplant. 2005; 35(Suppl 1):S77–S81.

44 44. Sonis ST, Woods PD, White BA. Oral complications of cancer therapies. Pretreatment oral assessment. NCI Monogr. 1990;( 9):29–32.

45 45. Yao S, Smiley SL, West K, et al. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16:1130–1137.

46 46. Campbell S, Sun CL, Kurian S, et al. Predictors of avascular necrosis of bone in long‐term survivors of hematopoietic cell transplantation. Cancer. 2009; 115:4127–4135.

47 47. Syrjala KL, Langer SL, Abrams JR, et al. Late effects of hematopoietic cell transplantation among 10‐year adult survivors compared with case‐matched controls. J Clin Oncol. 2005; 23:6596–6606.

48 48. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17:1072–1078.

49 49. Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. 2011; 29:2397–2404.

50 50. Sostak P, Padovan CS, Eigenbrod S, et al. Cerebral angiitis in 4 patients with chronic GVHD. Bone Marrow Transplant. 2010; 45:1181–1188.

51 51. Saad AG, Alyea E, Wen P, et al. Graft‐versus‐host disease of the CNS after allogeneic bone marrow transplantation. J Clin Oncol. 2009; 27:e147–e149.

52 52. Rusiewicz A, DuHamel KN, Burkhalter J, et al. Psychological distress in long‐term survivors of hematopoietic stem cell transplantation. Psychooncology. 2008; 17:329–337.

53 53. Pereira DB, Christian LM, Patidar S, et al. Spiritual absence and 1‐year mortality after hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2010; 16(8):1171–1179.

54 54. Sun CL, Francisco L, Baker KS, et al. Adverse psychological outcomes in long‐term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood. 2011; 118:4723–4731.

55 55. Wong FL, Francisco L, Togawa K, et al. Long‐term recovery after hematopoietic cell transplantation: predictors of quality‐of‐life concerns. Blood. 2010; 115:2508–2519.

56 56. Bishop MM, Beaumont JL, Hahn EA, et al. Late effects of cancer and hematopoietic stem‐cell transplantation on spouses or partners compared with survivors and survivor matched controls. J Clin Oncol. 2007; 25:1403–1411.

57 57. Armenian SH, Sun CL, Vase T, et al. Cardiovascular risk factors in hematopoietic cell transplantation (HCT) survivors: role in development of subsequent cardiovascular disease. Blood. 2012; 120(23):4505–4512.

58 58. Tichelli A, Passweg J, Wójcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008; 93:1203–1210.

59 59. Tichelli A, Rovo A, Passweg J, et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol. 2009; 2:583–601.

60 60. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009; 113:1175–1183.

61 61. Kolb HJ, Socie G, Duell T, et al. Malignant neoplasms in long‐term survivors of bone marrow transplantation (Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group). Ann Intern Med. 1999; 131:738–744.

62 62. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996; 87:3633–3639.

63 63. Gallagher G, Forrest DL. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer. 2007; 109:84–92.

64 64. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012; 62(2):118–128.

65 65. Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem‐cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol. 2007; 25:2449–2454.

66 66. Leisenring W, Friedman DL, Flowers ME, et al. Non‐melanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006; 24:1119–1126.

67 67. Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT‐Late Effect Working Party. Blood. 2008; 111:939–944.

68 68. Nakamizo A, Akagi Y, Amano T, et al. Donor‐derived adult T‐cell leukaemia. Lancet. 2011; 377:1124.

69 69. Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011; 17:771–789.

70 70. Krenauer A, Moll A, Pönisch W, et al. EBV‐associated post‐transplantation B‐cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression – a case report. Diagn Pathol. 2010; 5:21.

71 71. Snyder MJ, Stenzel TT, Buckley PJ, et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol. 2004; 28(6):794–800.

72 72. Gandelman JS, Byrne MT, Mistry AM, et al. Machine learning reveals chronic graft‐versus‐host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. Haematologica. 2019; 104(1):189–96.

73 73. Wang X, Sun CL, Quinones‐Lombrana A, et al. CELF4 variant and anthracycline‐related cardiomyopathy: a children’s oncology group genome‐wide association study. J Clin Oncol. 2016; 34(8):863.

74 74. Peled JU, Gomes AL, Devlin SM, et al. Microbiota as predictor of mortality in allogeneic hematopoietic‐cell transplantation. N Engl J Med. 2020; 382(9):822–834.

75 75. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic‐cell transplantation. N Engl J Med. 2010; 363:2091–2101.

76 76. Inamoto Y, Valdés‐Sanz N, Ogawa Y, et al. Ocular graft‐versus‐host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019; 54(5):662–673.

77 77. DeFilipp Z, Duarte RF, Snowden JA, et al. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplant. 2017; 52(2):173–182.

78 78. Buchbinder D, Kelly DL, Duarte RF, et al. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018; 53(5):535–555.

79 79. Inamoto Y, Shah NN, Savani BN, et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant 2015; 50(8): 1013–1023.